Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Actinogen Medical

Executive interview – Actinogen Medical

Actinogen Medical — 5 videos in collection

More on this equity

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. Primary indication is cognitive impairment in mild AD patients and results from the ongoing Phase II XanADu trial are expected to be announced in Q219. In this video, the company’s chief executive officer Bill Ketelbey introduces the company and lead asset, and provides an overview of R&D progress and expected news flow.

< Previous
Next >

You may also be interested in these:

Healthcare

Actinogen Medical – executive interview

Healthcare

Actinogen Medical - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free